By physician referral or invitation only

Study of VAL-413 in Patients with Recurrent Pediatric Solid Tumors

To establish the recommended Phase II dose of a flavored preparation of orally administered irinotecan (VAL-413) when given in combination with temozolomide for 5 consecutive days.

Age & Gender

1 years ~ 30 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Patrick Thompson
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Pediatric Cancers, Sarcoma (bone and soft tissue), Phase 1 Trials (all cancers))

IRB Number

22-2142

ClinicalTrials.gov

NCT04337177

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.